ANI Pharmaceuticals ANIP Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's total costs & expenses?
- ANI Pharmaceuticals (ANIP) reported total costs & expenses of $198.57M in Q1 2026.
- How has ANI Pharmaceuticals's total costs & expenses changed year-over-year?
- ANI Pharmaceuticals's total costs & expenses increased by 16.2% year-over-year, from $170.93M to $198.57M.
- What is the long-term trend for ANI Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's total costs & expenses has grown at a 31.8% compound annual growth rate (CAGR), from $255.93M to $772.27M.
- What does total costs & expenses mean?
- This represents the aggregate of all operating and non-operating costs incurred by the company to generate revenue, including cost of goods sold, research and development, and administrative overhead. It serves as a comprehensive measure of the company's total cost structure and operational scale. Analyzing this metric relative to revenue growth provides insight into the company's overall operating leverage and cost management discipline.